In recent years, anti-PD-1/PD-L1 therapy has achieved better clinical efficacy in melanoma, renal cell carcinoma, non-small-cell lung cancer, and other tumors and is effective in the largest pathway of advanced and metastatic tumors. The gene discussed is CD274; the disease is renal cell carcinoma.